Bladder cancer is the second most common urologic malignancy. Up to 95% of the urinary bladder tumors are of epithelial origin, from which 90% are transitional neoplasms. However, small cell carcinoma of the urinary bladder is rare tumor accounting for<0.7% of bladder cancer, of which the pure form is extremely rare. A 53-year-old female presented to urosurgery outpatient department complaining of hematuria and burning micturition since 3 months. Ultrsonography showed a large heteroechoic mass filling whole of the bladder. Histopathological examination of the transurethral debulked tumor mass revealed small cell carcinoma, which was confirmed on immunohistochemistry. We report this case due to its rarity and to add on to literature.
INTRODUCTION
Small cell carcinoma of the bladder (SCCB) is rare and accounts for<0.7% of all cancers arising from the bladder. [1] Most are mixed tumors found in association with transitional carcinoma, whereas pure form is extremely rarer. The first case was described in 1981 by Cramer et al. [2] They are associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinomas, and mostly diagnosed at advanced stages like their pulmonary counterpart. Here, we present a case of 53-year-old patient diagnosed histologically as SCCB, treated with surgery and chemotherapy along with a brief review of the literature.
CASE REPORT
A 53-year-old female patient presented with 3 months history of hematuria associated with pain, passage of the blood clot in urine and burning micturition. On physical examination, there was no significant finding. Routine investigation revealed Hb 12.0 g%, blood urea 21 mg% and serum creatinine 1.0 mg%. Ultasonography showed a large heteroechoic mass measuring 6.8 cm × 7.4 cm × 11.4 cm filling whole of the bladder with extension along anterior and right lateral aspect of the bladder. The pelvic muscles and rectus abdominis appear not to be infiltrated. Few subcentimetric hypoechoic left para-aortic lymph nodes seen, largest measuring 8 mm in diameter [ Figure 1 ]. Liver, bilateral kidneys and prostate were normal. There was no evidence of ascites/pleural/pericardial effusion.
Debulking of the tumor mass under spinal and obturator block was performed and sent for histopathological examination. Grossly, multiple gray brown soft tissue pieces measuring together 6 cm × 5.5 cm × 5 cm were received. Microscopically the tumor was composed of uniform population of small round, mitotically active cells with hyperchromatic, overlapping nuclei and inconspicuous nucleoli. Areas of necrosis were also found [ Figure 2 ]. Immunohistochemical staining showed positive staining for synaptophysin, chromogranin and neuron specific enolase while negative staining for leukocyte common antigen. Cytokeratin showed intense cytoplasmic staining in fragments of transitional epithelium while mild positivity in tumor cells [ Figure 3 ]. Based on the morphological and immunohistochemical findings, she was diagnosed as having primary pure SCCB. Patient subsequently received platinum based chemotherapy and is on follow-up since 6 months, which have been uneventful.
DISCUSSION
Bladder cancer is the second most common urologic malignancy. In the western countries, it is the fourth most common cancer in men and the eighth most common cancer in women. [3] Up to 95% of the urinary bladder tumors are of epithelial origin, from which 90% are transitional neoplasms. [4] Primary SCCB is a rare disease that accounts for < 0.7% of all bladder cancers. [1, 5] The disease was initially described in 1981 by Cramer et al. [2] Pure SCCB is an unusual malignancy, and most of these tumors were mixed with urothelial cell carcinoma. [3] Gross hematuria is the most common symptom, and most of the patients are male smokers with a mean age of 66 years. Dysuria and irritative symptoms have been reported as the second most common symptoms. Urethral obstruction, weight loss, urinary tract infection, and ectopic adrenocorticotrophic hormone secretion have been reported occasionally. [6] Pathogenesis is uncertain; however, the multipotent stem cell theory applies best, which states that tumors arising from early multipotent stem cells exhibit a more diverse phenotype and show positivity for neuroendocrine markers. [7] Histologically, SCCB is indistinguishable from its pulmonary counterpart. The diagnosis is based on the criteria established by the WHO classification system. The tumor is composed of sheets of uniformly small, round, mitotically active cells with overlapping nuclei and evenly distributed chromatin with inconspicuous nucleoli; tumor necrosis and crush artifact are commonly seen. [3] Immunostaining analysis showed that cancerous cells expressed markers of neuroendocrine differentiation, including chromogranin, neural adhesion molecule and synaptophysin. [8] The optimal treatment strategy for bladder SCC is still unclear, but the combination of surgery, radiotherapy, and chemotherapy is presently used. [9] Radical cystectomy alone may be used only in small volume disease. Nevertheless, chemotherapy plays a prominent role in the management of these tumors. Like SCC of the lung, cisplatine-etoposide regimen is usually used in SCCB. [9] Radiotherapy can be performed to palliate brain metastases and symptomatic bone metastases. Recently, the use of chemotherapy and radiotherapy with bladder preservation protocol seems to be an attractive concept. [9] CONCLUSION Small cell carcinoma of the bladder is a rare and highly aggressive tumor, mostly diagnosed at advanced stage. The pure form is uncommon with a more adverse prognosis than the mixed form; however, both local treatment and chemotherapy seems to confer a more favorable outcome as seen in our case. In the future, identification of new molecular markers could be used in early diagnosis and targeted therapies. 
